• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Ezetimibe

Ezetimibe

Product ID E9819
Cas No. 163222-33-1
Purity ≥99%
Product Unit SizeCostQuantityStock
25 mg $63.00 In stock
100 mg $176.40 In stock
250 mg $404.30 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Ezetimibe is an inhibitor of Niemann-Pick-like C1-type 1 (NPC1L1) protein, a cholesterol transport protein, resulting in inhibition of intestinal cholesterol transport and decreases in LDL levels. Ezetimibe exhibits anti-hyperlipidemic, anti-atherosclerotic, anti-diabetic, nephroprotective, and hepatoprotective activities. In hepatocytes, ezetimibe decreases mTORC1 activity and increases autophagy, decreasing free cholesterol in the plasma membrane. In other in vitro models, ezetimibe inhibits expression of intracellular adhesion molecule 1 (ICAM-1) and CD11A/B, phosphorylation of ERK, and activation of NF-κB, decreasing adhesion of THP-1 cells and preventing them from differentiating into macrophage-like cells. In animal models of diabetes, this compound normalizes adiponectin levels, decreases plasma and hepatic lipids, and improves glomerular hypertrophy. Additionally, ezetimibe decreases generation of ROS, downregulates expression of skp2 and CDC20, and inhibits degradation of microsomal triglyceride transfer protein (MTP), improving fibrosis and steatosis in animal models of nonalcoholic fatty liver disease.

Product Info

Cas No.

163222-33-1

Purity

≥99%

Formula

C24H21F2NO3

Formula Wt.

409.43

IUPAC Name

(3R, 4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4- hydroxyphenyl)azetidin-2-one

Melting Point

164-166°C

Appearance

White to off white powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

E9819 MSDS PDF

Info Sheet

E9819 Info Sheet PDF

References

Yamamura T, Ohsaki Y, Suzuki M, et al. Inhibition of NPC1L1 by ezetimibe activates autophagy in human hepatocyte and reduces mutant α1-antitrypsin Z deposition. Hepatology. 2013 Nov 9. [Epub ahead of print]. PMID: 24214142.

Wang X, Sugimoto K, Fujisawa T, et al. Novel effect of ezetimibe to inhibit the development of non-alcoholic fatty liver disease in Fatty Liver Shionogi mouse. Hepatol Res. 2014 Jan;44(1):102-13. PMID: 23510093.

Muñoz-Pacheco P, Ortega-Hernández A, Miana M, et al. Ezetimibe inhibits PMA-induced monocyte/macrophage differentiation by altering microRNA expression: a novel anti-atherosclerotic mechanism. Pharmacol Res. 2012 Dec;66(6):536-43. PMID: 22989505.

Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415-27. PMID: 22910633.

Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8132-7. PMID: 15928087.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • A5039

    Amitraz

    Insecticide; α-adrenergic agonist, MAO inhibit...

    ≥97%
  • T3041

    Thienylpropyl Isothiocyanate

    Thienylbutyl ITC analog.

    ≥98%
  • A7202

    AS-604850

    p110γ PI3K inhibitor.

    ≥98%
  • N3422

    Nifekalant Hydrochloride

    Voltage-gated K+ channel blocker.

    ≥98%
  • M2400

    MG-132

    Proteasome inhibitor.

    ≥98%
  • D3449

    Dimethoxycurcumin

    Curcumin derivative.

    ≥98%
  • A2420

    A-769662

    AMPK activator.

    ≥98%
  • A5170

    Amrinone

    Pyridine; PDE3 inhibitor.

    ≥98%
  • H9618

    Hydroquinone

    Basic phenol skeleton structure found in variou...

    ≥96%
  • K0652

    Kb NB 142-70

    PKD inhibitor.

    ≥98%
  • A7461

    Asperosaponin VI

    Triterpene saponin found in Dipsacus asper.

    ≥98%
  • D1631

    Dehydrocorydaline

    Alkaloid compound originally found in Corydalis...

    ≥95%
  • K0040

    Kahweol Stearate

    Diterpene found in coffee beans.

    ≥98%
  • B7977

    Butylated Hydroxytoluene

    Antioxidative food and cosmetics additive.

    ≥99%
  • F1655

    Fenoprofen Calcium Dihydrate

    NSAID; COX-1/2 inhibitor.

    ≥97%
  • A9912

    AZD-7762 Hydrochloride

    CHK1 inhibitor.

    ≥98%
  • G3454

    Ginsenoside Rb1

    Triterpene saponin found in species of Panax. <...

    ≥98%
  • B030967

    BAY-1895344

    ATR inhibitor.

    ≥99%
  • P5878

    Potassium Canrenoate

    Aldosterone antagonist.

    ≥98%
  • M0275

    Mastoparan 17

    Peptide, inactive mastoparan analog used to mea...

    ≥95%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only